Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard...

詳細記述

保存先:
書誌詳細
出版年:Am J Hematol
主要な著者: Larsen, Jeremy T., Shanafelt, Tait D., Leis, Jose F., LaPlant, Betsy, Call, Tim, Pettinger, Adam, Hanson, Curtis, Erlichman, Charles, Habermann, Thomas Matthew, Reeder, Craig, Nikcevich, Daniel, Bowen, Deborah, Conte, Michael, Boysen, Justin, Secreto, Charla, Lesnick, Connie, Tschumper, Renee, Jelinek, Diane, Kay, Neil E., Ding, Wei
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507724/
https://ncbi.nlm.nih.gov/pubmed/28402581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24762
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料